Achieving Excellence in Peripheral Artery Disease and Chronic Limb-Threatening Ischemia Care

Listen

0:00 / 0:00

This resource was sponsored by Johnson & Johnson.

This actionable resource presents best practices on developing a standardized care program that includes workflow integration, provider engagement, and program assessment tools for managing peripheral artery disease and chronic limb-threatening ischemia.

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Achieving Excellence in Peripheral Artery Disease and Chronic Limb-Threatening Ischemia Care

Trending on AJMC

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer

More Women Will Be Diagnosed With MCL Through 2032, SEER Data Suggest

Health Care Spending to Hit $9 Trillion by 2034, According to New Analysis

EHA Data for Epcoritamab Show Durable Responses in Older, Chemotherapy-Ineligible Patients With DLBCL

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Achieving Excellence in Peripheral Artery Disease and Chronic Limb-Threatening Ischemia Care

Trending on AJMC

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer

More Women Will Be Diagnosed With MCL Through 2032, SEER Data Suggest

Health Care Spending to Hit $9 Trillion by 2034, According to New Analysis

EHA Data for Epcoritamab Show Durable Responses in Older, Chemotherapy-Ineligible Patients With DLBCL